[go: up one dir, main page]

PE20081482A1 - Capsulas de gelatina que contienen un acido - Google Patents

Capsulas de gelatina que contienen un acido

Info

Publication number
PE20081482A1
PE20081482A1 PE2007001792A PE2007001792A PE20081482A1 PE 20081482 A1 PE20081482 A1 PE 20081482A1 PE 2007001792 A PE2007001792 A PE 2007001792A PE 2007001792 A PE2007001792 A PE 2007001792A PE 20081482 A1 PE20081482 A1 PE 20081482A1
Authority
PE
Peru
Prior art keywords
acid
composition
refers
filling material
gelatin capsule
Prior art date
Application number
PE2007001792A
Other languages
English (en)
Inventor
Isabel Ottinger
Agnes Taillardat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37890457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081482(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081482A1 publication Critical patent/PE20081482A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE CAPSULA DE GELATINA LA CUAL COMPRENDE: a) UNA CUBIERTA DE CAPSULA DE GELATINA BLANDA Y b) UN MATERIAL, SEMILIQUIDO O LIQUIDO COMO MICROEMULSION, DE RELLENO; EL CUAL CONTIENE ENTRE 0.01% AL 20% DE UN ACIDO, SELECCIONADO DE ACIDO FUMARICO, ACIDO FOSFORICO, ACIDO MALICO, ACIDO ASCORBICO, ENTRE OTROS, EN EL QUE DICHO ACIDO MIGRA DESDE EL MATERIAL DE RELLENO HACIA LA CUBIERTA DE CAPSULA E INHIBE LA FORMACION DE PELICULA; EL AGENTE ACTIVO PUEDE ESTAR PRESENTE EN HASTA UN 20% DEL PESO TOTAL DE LA COMPOSICION. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHA COMPOSICION CONTIENE PREFERENTEMENTE 7-TERBUTOXI-IMINO-METIL-CAMPTOTECINA QUE ES UN INHIBIDOR DE TOPOISOMERASA I, UTIL EN EL TRATAMIENTO DE CANCER
PE2007001792A 2006-12-20 2007-12-14 Capsulas de gelatina que contienen un acido PE20081482A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06126698 2006-12-20

Publications (1)

Publication Number Publication Date
PE20081482A1 true PE20081482A1 (es) 2008-12-23

Family

ID=37890457

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001792A PE20081482A1 (es) 2006-12-20 2007-12-14 Capsulas de gelatina que contienen un acido

Country Status (15)

Country Link
US (1) US20100068265A1 (es)
EP (1) EP2120889A1 (es)
JP (1) JP2010513351A (es)
KR (1) KR20090094373A (es)
CN (1) CN101563072A (es)
AR (1) AR064419A1 (es)
AU (1) AU2007334856A1 (es)
BR (1) BRPI0720489A2 (es)
CA (1) CA2672400A1 (es)
CL (1) CL2007003698A1 (es)
MX (1) MX2009006735A (es)
PE (1) PE20081482A1 (es)
TW (1) TW200833375A (es)
UY (1) UY30810A1 (es)
WO (1) WO2008074479A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5829607B2 (ja) * 2010-06-30 2015-12-09 持田製薬株式会社 ω３脂肪酸の配合製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60239418A (ja) * 1984-05-15 1985-11-28 Nippon Kayaku Co Ltd エトポシド軟カプセル製剤
DE4001622A1 (de) * 1990-01-20 1991-07-25 Thomae Gmbh Dr K Orale arzneimittelformen von pimobendan
US5620704A (en) * 1994-11-07 1997-04-15 Warner-Lambert Company Process for stabilizing gelatin products
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
WO1997033568A1 (en) * 1996-03-12 1997-09-18 Novartis Ag Filled gelatin capsules having a reduced degree of cross-linking
US6228894B1 (en) * 1998-04-17 2001-05-08 Enhanced Derm Technologies, Inc. Softgel-compatible composition containing retinol
ATE387191T1 (de) * 2002-04-25 2008-03-15 Banner Pharmacaps Inc Kaubare weichkapsel
NZ537022A (en) * 2002-06-05 2006-10-27 Ivax Pharmaceuticals S Reduction of gelatin cross-linking in the gelatin shell of gelatin capsules by incorporating a free amino acid into the capsule shall and a carboxylic acid ester into the capsule filling

Also Published As

Publication number Publication date
AR064419A1 (es) 2009-04-01
CA2672400A1 (en) 2008-06-26
WO2008074479A1 (en) 2008-06-26
MX2009006735A (es) 2009-06-30
UY30810A1 (es) 2008-07-31
TW200833375A (en) 2008-08-16
KR20090094373A (ko) 2009-09-04
CL2007003698A1 (es) 2008-07-18
US20100068265A1 (en) 2010-03-18
JP2010513351A (ja) 2010-04-30
EP2120889A1 (en) 2009-11-25
BRPI0720489A2 (pt) 2014-02-04
CN101563072A (zh) 2009-10-21
AU2007334856A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
CO6290641A2 (es) Preparacion de capsula que contiene los ingredientes farmaceuticamente activos liquidos y solidos, la cual presenta exelentes propiedades de los ingredientes farmaceuticamente activos
DOP2017000190A (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas
PE20080765A1 (es) Formas de dosificacion farmaceutica
PE20120923A1 (es) Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo
WO2007143652A3 (en) Chewable soft gelatin capsules
PE20061136A1 (es) Sistema de capsulas blandas que no son de gelatina
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
ECSP15039103A (es) Formulación de liberación sostenida de mosapride que proporciona efectos farmacológicos y clínicos con administración una vez al día
CR20120400A (es) Pastillas de gelatina blanda con nicotina
BRPI0707334A8 (pt) formulação de cápsula de gelatina mole e método para estabilização de um composto 15-ceto-prostaglandina
AR049137A1 (es) Formulacion de irinotecan en vesicula cerrada, para el tratamiento del cancer
DOP2010000318A (es) Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente
PE20060002A1 (es) Combinaciones antineoplasicas de cci-779 y rituximab
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
AR088918A1 (es) Composiciones antitranspirantes anhidras
SI3060203T1 (en) A effervescent tablet containing a high level of aspirin
PE20081482A1 (es) Capsulas de gelatina que contienen un acido
PE20081443A1 (es) Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas
MX2016000605A (es) Composiciones y dispositivos para atomizador antitranspirante.
ATE418540T1 (de) Galloylpeptide
CO2021015117A2 (es) Composición de naproxeno en cápsula blanda miniatura
PE20060639A1 (es) Composicion farmaceutica en forma de comprimido de residencia gastrica que contiene un principio activo
RU2019110955A (ru) ЛЕЧЕНИЕ НЕХОДЖКИНСКОЙ ЛИМФОМЫ ЛИЛОТОМАБОМ И 177Lu-ЛИЛОТОМАБ САТЕТРАКСЕТАНОМ
AR093275A1 (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos

Legal Events

Date Code Title Description
FD Application declared void or lapsed